REGENXBIO Files Q1 2025 10-Q
Ticker: RGNX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1590877
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, SEC filing
TL;DR
REGENXBIO's Q1 2025 10-Q is in. Check financials and stock info.
AI Summary
REGENXBIO Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and operational details are presented in this filing, including information related to employee stock options and restricted stock units.
Why It Matters
This filing provides investors with an update on REGENXBIO's financial health and operational status for the first quarter of 2025, crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, REGENXBIO faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250512 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- REGENXBIO Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- Nippon Shinyaku (company) — Party to a collaboration and license agreement
- AbbVie (company) — Party to a collaboration and license agreement
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 12, 2025.
What is REGENXBIO Inc.'s fiscal year end?
REGENXBIO Inc.'s fiscal year ends on December 31st.
Are there any collaboration and license agreements mentioned?
Yes, the filing mentions collaboration and license agreements with Nippon Shinyaku and AbbVie.
What types of stock-based compensation are referenced?
The filing references employee stock, employee stock options, and restricted stock units (RSUs).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding REGENXBIO Inc. (RGNX).